Streptococcus pyogenes or invasive Group A Streptococcus (iGAS) is a major clinical concern around the world, since iGAS ...

A 15-year retrospective study in adults admitted to the intensive care department at Donostia University Hospital has revealed crucial insights into invasive Streptococcus pyogenes (iGAS) infections.

Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology ...

Streptococcus pyogenes or invasive Group A Streptococcus (iGAS) is a major clinical concern around the world, since iGAS infections can quickly ...

Pelthos Therapeutics has secured the rights to market non-fluorinated quinolone antimicrobial, Xepi (ozenoxacin) cream, 1% in ...

Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™Xepi is a novel FDA-approved topical treatment ...

Biopharma company Pelthos Therapeutics has acquired the US commercialization rights to Xepi (ozenoxacin) Cream, 1%, from ...

Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMIXepi is a novel FDA-approved topical treatment for impetigo that addresses a critical unmet need in anti ...

DelveInsight's Antibody-mediated Rejection Market Insights report includes a comprehensive understanding of current treatment ...

Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and ...

Xepi is a non-fluorinated quinolone antimicrobial cream approved by the FDA in 2017 for treating impetigo in patients two months and older. The treatment targets infections caused by Staphylococcus ...

Results from an interim analysis in the Phase 2 STARBORN-1 trial of TARA-002 in pediatric LMs patients remain on track for 4Q 2025Expect to ...